Novartis receives Health Canada approval for Mayzent (siponimod) to treat secondary progressive multiple sclerosis with active disease
N
ovartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has approved MayzentTM (siponimod) for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.
SPMS follows a relapsing-remitting (RRMS) course of multiple sclerosis (MS) and is characterized by progressive worsening with fewer, or no relapses, and nerve damage or loss4. SPMS is defined as active when individuals experience relapses or there is evidence of new MRI activity.
One of the top treatment goals for individuals with MS is delaying disability progression and we're delighted to deliver the first and only oral treatment proven to slow disease progression in those with active SPMS, said Dawn Bell, Chief Scientific Officer and VP Medical Affairs, Novartis Canada. The approval of MayzentTM is a testament to our relentless commitment to reimagine MS treatment.
People living with SPMS experience changes in their MS symptoms with fewer or no relapses, and there can be minor remissions and plateaus6. Progression most frequently includes mobility issues, which may lead to the need for walking aids, bladder dysfunction, and cognitive decline7.
We are pleased to see that Health Canada has approved an additional therapeutic advancement targeting progressive forms of the disease. MS is unpredictable. The more treatment options for people with MS, the more opportunities they have in managing their individual symptoms throughout their MS journey, said Dr. Pamela Valentine, President and CEO, MS Society of Canada.
As the first oral therapy specifically approved for SPMS, MayzentTM may help those living with active SPMS by slowing disease progression, said Dr. Mark S. Freedman, Professor of Medicine, Department of Medicine, University of Ottawa.
✔️ Novartis receives Health Canada approval for Mayzent (siponimod) to treat secondary progressive multiple sclerosis with active disease
💕 Found this article helpful? Spread the word and support us!